CN1635887A - α－2－δ配体与选择性环加氧酶－2抑制剂的组合 - Google Patents

α－2－δ配体与选择性环加氧酶－2抑制剂的组合 Download PDF

Info

Publication number
CN1635887A
CN1635887A CNA038043564A CN03804356A CN1635887A CN 1635887 A CN1635887 A CN 1635887A CN A038043564 A CNA038043564 A CN A038043564A CN 03804356 A CN03804356 A CN 03804356A CN 1635887 A CN1635887 A CN 1635887A
Authority
CN
China
Prior art keywords
aminomethyl
acetic acid
cyclopentyl
methyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038043564A
Other languages
English (en)
Chinese (zh)
Inventor
小查尔斯·P·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1635887A publication Critical patent/CN1635887A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA038043564A 2002-02-22 2003-02-12 α－2－δ配体与选择性环加氧酶－2抑制剂的组合 Pending CN1635887A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US60/359,295 2002-02-22
US40436502P 2002-08-19 2002-08-19
US60/404,365 2002-08-19

Publications (1)

Publication Number Publication Date
CN1635887A true CN1635887A (zh) 2005-07-06

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038043564A Pending CN1635887A (zh) 2002-02-22 2003-02-12 α－2－δ配体与选择性环加氧酶－2抑制剂的组合

Country Status (21)

Country Link
US (1) US20030199567A1 (https=)
EP (1) EP1480639A1 (https=)
JP (1) JP2005523281A (https=)
KR (1) KR20040085216A (https=)
CN (1) CN1635887A (https=)
AR (1) AR038531A1 (https=)
AU (1) AU2003246864A1 (https=)
BR (1) BR0307906A (https=)
CA (1) CA2476438A1 (https=)
CO (1) CO5611109A2 (https=)
HN (1) HN2003000071A (https=)
IL (1) IL162932A0 (https=)
MX (1) MXPA04008175A (https=)
NO (1) NO20043947L (https=)
PA (1) PA8567201A1 (https=)
PE (1) PE20031052A1 (https=)
PL (1) PL372210A1 (https=)
RU (1) RU2286151C2 (https=)
TW (1) TW200303214A (https=)
UY (1) UY27675A1 (https=)
WO (1) WO2003070237A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054560A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
NZ545494A (en) * 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
AR060404A1 (es) * 2006-04-11 2008-06-11 Novartis Ag Compuestos organicos utiles como inhibidores de dipeptidil-peptidasa iv
US20130012485A1 (en) * 2006-12-22 2013-01-10 Baeschlin Daniel Kaspar Organic compounds
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
SI2735338T1 (sl) * 2008-09-05 2019-04-30 Grunenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
JP2023548380A (ja) * 2020-10-28 2023-11-16 トレモー・ファーマシューティカルズ・インコーポレイテッド 非水溶性ｃｏｘ－２阻害の水性製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
RU2168982C2 (ru) * 1994-07-27 2001-06-20 Варнер-Ламберт Компани Способ лечения состояния страха или лечения и/или предупреждения состояния паники, очищенный белок, способный связывать габапентин, и фармацевтическая композиция, обладающая успокоительным, противопаническим и противосудорожным действием
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
CA2304967C (en) * 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
US6451857B1 (en) * 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
JP2003516353A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション ヴァルデコキシブ組成物

Also Published As

Publication number Publication date
PE20031052A1 (es) 2003-12-24
PL372210A1 (en) 2005-07-11
AR038531A1 (es) 2005-01-19
MXPA04008175A (es) 2004-11-26
BR0307906A (pt) 2004-12-21
EP1480639A1 (en) 2004-12-01
IL162932A0 (en) 2005-11-20
CO5611109A2 (es) 2006-02-28
HN2003000071A (es) 2003-11-24
AU2003246864A1 (en) 2003-09-09
CA2476438A1 (en) 2003-08-28
RU2286151C2 (ru) 2006-10-27
PA8567201A1 (es) 2003-11-12
KR20040085216A (ko) 2004-10-07
WO2003070237A1 (en) 2003-08-28
US20030199567A1 (en) 2003-10-23
NO20043947L (no) 2004-09-21
RU2004125609A (ru) 2006-01-27
UY27675A1 (es) 2003-09-30
JP2005523281A (ja) 2005-08-04
TW200303214A (en) 2003-09-01

Similar Documents

Publication Publication Date Title
CN1726015A (zh) 不同药物用途的α2δ配体
CN1635887A (zh) α－2－δ配体与选择性环加氧酶－2抑制剂的组合
CN1299683C (zh) 塞内昔布组合物
CN1279617A (zh) 醛糖还原酶抑制剂和糖原磷酸化酶抑制剂的组合物
CN1253150C (zh) 单独的或与抗血小板聚集药物联合的Xa因子抑制剂
CN1407887A (zh) 口服液体组合物
CN1358095A (zh) 使用mek抑制剂治疗慢性疼痛的方法
CN1805743A (zh) 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
CN1878546A (zh) 治疗抑郁症和焦虑症的包括α－2δ配体和SSRI和/或SNRI的联用药物
CN1747730A (zh) 肝细胞生长因子(分散因子)活性的吡唑衍生物调节剂
CN1575182A (zh) 用于治疗和预防疼痛和炎症的含环加氧酶－2选择性抑制剂和硫酸软骨素的组合物
CN1658863A (zh) 重症脓毒病预防治疗药物
CN1886124A (zh) 抑制残余脂蛋白产生的方法
CN101031291A (zh) 包含甲醇化合物和至少一种nsaid的活性物质组合
CN1678297A (zh) 治疗骨关节炎的方法
CN1638760A (zh) 用环加氧酶－2选择性抑制剂和阿司匹林的组合治疗疼痛、炎症和炎症相关疾病
CN1564687A (zh) 磷酸二酯酶iv抑制剂的用途
HK1074787A (en) Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
CN1133287A (zh) 角鲨烯合成酶抑制剂
CN101052420A (zh) 用于治疗自体免疫疾病的并用药
CN1678298A (zh) α2δ配体如加巴喷丁或普瑞巴林用于治疗注意力缺陷的过度反应症的用途
CN1507870A (zh) 解热、镇痛、抗炎、抗血小板聚集的药物组合物及其制备
CN1761655A (zh) 噻唑衍生物及其作为vap－1抑制剂的用途
CN1771034A (zh) 过氧化物酶体增殖物激活受体－α激动剂和环加氧酶－2选择性抑制剂的组合及其治疗用途
CN1625412A (zh) 预防或治疗心血管疾病的醛甾酮拮抗剂和非－甾族抗炎剂的组合疗法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074787

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1074787

Country of ref document: HK